aTyr Pharma
ATYR
41 hedge funds and large institutions have $77M invested in aTyr Pharma in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 8 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
35% more call options, than puts
Call options by funds: $218K | Put options by funds: $161K
11% more funds holding
Funds holding: 37 → 41 (+4)
6% more capital invested
Capital invested by funds: $72.8M → $77M (+$4.25M)
0.49% more ownership
Funds ownership: 65.21% → 65.7% (+0.49%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.27M |
| 2 |
Renaissance Technologies
New York
|
+$805K |
| 3 |
Millennium Management
New York
|
+$769K |
| 4 |
Man Group
London,
United Kingdom
|
+$670K |
| 5 |
Two Sigma Investments
New York
|
+$644K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.67M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.24M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$584K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$433K |
| 5 |
JP Morgan Chase
New York
|
-$165K |
ATYR Hedge Fund Activity: Q2 2023 in Review
41 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2023, worth a combined $77M — up 5.8% from $72.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ATYR positions and 8 closed out — a net gain of 4 holders — while 18 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $2.27M. The largest seller was Samsara BioCapital, exiting entirely with an estimated $3.67M sold.
- 41 institutional investors held aTyr Pharma (ATYR) as of Q2 2023, up from 37 in Q1 2023.
- Funds reported $77M of aTyr Pharma stock for Q2 2023, up 5.8% quarter-over-quarter.
- 12 funds opened new aTyr Pharma positions in Q2 2023 and 8 closed out, a net change of +4 holders.
- The largest aTyr Pharma buyer in Q2 2023 was BlackRock, an estimated $2.27M added.
- The largest aTyr Pharma seller in Q2 2023 was Samsara BioCapital, an estimated $3.67M sold.
Based on aggregated 13F filings for Q2 2023.